We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
22 November 2021
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company, has launched its Level 1 American Depositary Receipt ("ADR") program in the United States. As of 18 November 2021, ADRs may be traded over the counter. Relief's ADR program complements its existing primary listing of shares on the SIX Swiss Exchange. J.P. Morgan has been appointed as the depositary bank for the ADR program.
VISCHER advised Relief on the Swiss legal aspects under this ADR program. The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprised Dr. Peter Kühn (Counsel, Corporate/M&A), Christian Schneiter (Senior Associate, Corporate/M&A) and Christoph Niederer (Partner, Tax).
Categories: Mergers & Acquisitions, Tax
Opt-in for our regular updates, news, views, insights and more.